Skip to main content
NewslettersWatchlist
hello world

Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Stocks in play: Numinus Wellness Inc.

Baystreet.ca - Baystreet - Mon Aug 12, 9:03AM CDT

Comments on the U.S. Food and Drug Administration's decision to not approve Lykos Therapeutics' new drug application for MDMA (midomafetamine capsules) used in combination with psychological intervention for individuals with post-traumatic stress disorder. According to a news release issued by Lykos Therapeutics, the FDA has requested that an additional Phase 3 study be conducted to study the safety and efficacy of MDMA further. Numinus Wellness Inc. shares T.NUMI are trading down $0.01 at $0.04.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).